Biogen to acquire Apellis Pharmaceuticals for $41 per share in cash plus contingent value rights, valuing the deal at about $5.6 billion
https://finviz.com/quote.ashx?t=APLS&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.